ÌÇÐÄVlog

A Scottish research company is designing a new generation of antibiotics using academic expertise to combat drug-resistant bacteria such as the hospital "superbug" methicillin-resistant Staphylococcus aureus (MRSA). MGB Biopharma is to commercialise a new class of antibacterial product based on University of Strathclyde research. About £2 million in funding has been secured for the project, which uses technology licensed from Strathclyde. So far it has shown positive results in combating gram-negative and gram-positive bacteria, including MRSA.